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1 |  INTRODUCTION
COVID-19 (coronavirus disease 2019) has affected more 
than 4 million people worldwide. Its prominent presentation 
is respiratory symptoms which can progress to severe pneu-
monia, respiratory failure and shock; however, many patients 
may present cardiovascular manifestations.1-4
Although the awareness regarding the adverse impact 
of cardiovascular involvement on prognosis and the cardio-
vascular manifestations of COVID-19 is increasing, the dis-
crimination between the COVID-19 and non-COVID-related 
cardiovascular etiologies may be challenging.2,4-9
The concerns about the COVID-19 may result in a 
delay in proper approach and prompt management in many 
emergent and urgent medical conditions, such as cardiovas-
cular problems.
Our center is a tertiary center for cardiovascular medicine in 
Iran, and as it mainly caters for cardiovascular-related problems, 
patients with specific symptoms for COVID-19 were not referred 
to our center, because they were transferred to the COVID-19 
specific centers. However, encountering patients infected by the 
novel coronavirus is inevitable during the pandemic.
In this case series, we report the story of four cases hos-
pitalized in our center with different cardiovascular-related 
manifestations at first presentation and suspicious of COVID-
19 after primary workups. Like other centers throughout the 
world, we aim to present our challenges in the management 
of these patients and report their final destiny.
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Abstract
Different cardiovascular presentations of coronavirus disease 2019 can be seen be-
cause of the systemic involvement. Considering its new presentations, there is need 
for further studies regarding the mechanistic pathways involved.
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2 |  CASE REPORT
2.1 | Case 1
2.1.1 | Case history
A 55-year-old man with compressive angina, fever, and 
dyspnea but no cough and myalgia and reported history of 
close contact with a COVID-19-positive patient is presented. 
He had a history of hypertension in treatment with captopril 
and metoprolol succinate.
On admission, he had oxygen saturation (SPO2) of 95%, 
blood pressure of 100/70 mm Hg, and heart rate of 100 bpm. 
His temperature was 38 degrees Celsius. The physical exam-
ination was unremarkable except for diffuse bilateral crackles.
2.1.2 | Differential diagnosis, 
investigations, and treatment
His electrocardiogram (ECG) showed a nonspecific pattern: 
Normal sinus rhythm (NSR), right axis deviation, Left atrial 
abnormality, widening of QRS in limb leads and tall R wave 
in V1-V3 as well as ST elevation in V2-V6 (Figure 1-Panel 
A). The main laboratory findings are presented in Table 1. 
The kidney function tests were normal but liver enzymes 
were elevated significantly (AST = 269 IU/L and ALT = 276 
[normal up to 40]), with normal alkaline phosphatase.
Transthoracic echocardiogram (TTE) showed normal LV 
size, left ventricular ejection fraction (LVEF) of about 45% 
without RWMA, a grade one of LV diastolic dysfunction 
and normal pulmonary artery pressure (PAP). The first chest 
computed tomography (CT) showed typical ground-glass 
opacification (GGO) pattern in both lungs (Figure  1-Panel 
B).
He was admitted in monitored bed at the COVID-specific 
ward, and nasopharyngeal swab specimen was taken for re-
verse transcription polymerase chain reaction (RT-PCR) for 
COVID-19, which was reported positive the following day. 
At the second day of admission, his symptoms in terms of 
dyspnea aggravated, he developed dry cough, and his O2 
saturation dropped to 75% without O2 therapy. He received 
hydroxychloroquine (HCQ) for 5  days at first line, but the 
pneumonitis was not controlled; thus, lopinavir/ritonavir 
(Kaletra) started for him by an infectionist, leading to im-
provement of his symptoms and SPO2.
He was ready for discharge after a negative RT-PCR, 2 days 
after the second chest CT; however, he developed severe an-
gina with identical ECG changes and a CTn-I of >50 µg/L; 
thus, the patient was emergently transferred to catheterization 
laboratory (Cath-Lab), where his selective coronary angiog-
raphy revealed three-vessel disease (Figure 1-Panel C).
2.1.3 | Outcome
Coronary bypass surgery was planned for the patient, but 
he refused and got better after intensification of antiangina 
therapies, echocardiography before discharge was not sig-
nificantly different from his baseline echo except for a mild 
decrease in left ventricular function (LVEF = 35%-40%) and 
he was discharged after about 2 months of hospitalization. 
His antihypertensive medications were continued during his 
hospitalization course. Figure 1-panel D shows his chest CT, 
F I G U R E  1  A, ECG of case 1 showing 
a nonspecific pattern: normal sinus rhythm 
(NSR), right axis deviation, left atrial 
abnormality, widening of QRS in limb leads 
and tall R wave in V1-V3 as well as ST 
elevation in V2-V6. B, Chest CT of case 1 
showing typical ground-glass opacification 
in both lungs. C, Selective coronary 
angiography of case 1 revealing three-
vessel disease. D, Chest CT of case 1 after 
treatment without coronavirus involvement
(A) (C)
(B) (D)
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35 days after completion of therapies which depicts that the 
pneumonitis is fully resolved. The ECG changes were re-
solved, and the CTn-I returned to normal.
2.2 | Case 2
2.2.1 | Case history
A 61-year-old man with acute-onset angina chest pain with-
out fever, a sore throat, dyspnea, cough, myalgia, and no his-
tory of close contact with a COVID-19-positive patient is 
presented. He had past history of hypertension, smoking, and 
chronic obstructive pulmonary disease. He was addicted to 
opium and had a recent history of percutaneous coronary in-
tervention (PCI) on left anterior descending (LAD) artery and 
right coronary artery (RCA) 2 months before. He was under 
treatment with valsartan, aspirin, bisoprolol, furosemide, 
spironolactone, nitroglycerin, clopidogrel, and atorvastatin.
On presentation, he had SPO2  =  94%, blood pres-
sure = 140/80 mm Hg, heart rate = 90, and temperature = 37. 
The physical examination was unremarkable save diffuse bi-
lateral crackles, and systolic murmur at apex and left sternal 
border.
2.2.2 | Differential diagnosis, 
investigations, and treatment
His electrocardiogram (ECG) showed ST-segment eleva-
tion in anterior precordial leads (Figure 2-panel A).The main 
laboratory findings are presented in Table 1. The kidney and 
liver function tests were normal. The diagnosis was acute an-
terior ST-elevation myocardial infarction (MI), and he was 
emergently transferred to the Cath-Lab and underwent pri-
mary PCI on LAD due to stent thrombosis (Figure 2-panel 
B). He received Integrilin after the procedure with a dose of 
2 µg/kg/min for 48 hours.
Echocardiography just after primary PCI revealed normal 
LV size, LVEF = 25%, anterior wall akinesia, severe hypokine-
sia of anterolateral, and lateral walls, grade I LV diastolic dys-
function, moderate mitral regurgitation (MR), and normal PAP.























Case 1 15.2 14 900 1490 12 814 280 000 40 9 2.33 2.33 Positive
Case 2 13.7 9000 801 7974 226 000 13 1 6.39 1.58 Positive
Case 3 9.2 10 300 2060 7725 248 000 90 98 0.19 3.12 Positive
Case 4 14.6 16 610 1063 15 148 229 000 4 30 0.15 – Negative
Abbreviations: COVID-19, coronavirus disease 2019; CTn-I, cardiac troponin I; ESR, erythrocyte sedimentation rate; Hg, hemoglobin; hs-CRP, high-sensitivity 
C-reactive protein; PMN, polymorphonuclear; RT-PCR, reverse transcription polymerase chain reaction; WBC, white blood cells.
aNormal value: <6 mg/L. 
bNormal value: <0.03 mcg/L. 
cNormal value: <0.5 mcg/mL. 
F I G U R E  2  A, ECG of case 2 showing 
ST-segment elevation in anterior precordial 
leads. B, Angiographic view of case 2 
showing stent thrombosis in LAD. C, Chest 
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The next day, he developed dry cough and his chest CT 
examination was typical for COVID-19 (Figure 2-panel C). 
He was transferred to the COVID-19-specific monitored 
bed, and the nasopharyngeal swab specimen was positive for 
COVID-19 in RT-PCR test.
He also received HCQ for 5 days accompanied with his 
cardiac medications standard for MI. The disease course was 
uneventful, the ECG changes improved, and the LVEF in-
creased to 35%.
2.2.3 | Outcome
He was discharged with self-consent, having decent clinical 
conditions on discharge without chest pain or cough. He was 
advised to be isolated, and all family members were edu-
cated. The patient had good clinical condition upon phone 
follow-up.
2.3 | Case 3
2.3.1 | Case history
A 61-year-old lady with nausea, vomiting, weakness, dysp-
nea, and orthopnea was a known case of hypertension, diabe-
tes mellitus, and end-stage renal disease. She had also a right 
kidney mass diagnosed about 2 months before and was under 
workup. She had been under hemodialysis 3 days per week 
and also had a history of permanent pacemaker implantation 
2  months before her last admission due to complete heart 
block. She was on statins, insulin, and calcitriol.
On physical examination, she had SPO2 = 82%, which im-
proved to 96% with nasal O2, blood pressure = 90/60 mm Hg, 
and heart rate = 100 bpm and no fever. No other remarkable 
finding was noted.
2.3.2 | Differential diagnosis, 
investigations, and treatment
Electrocardiogram showed pacemaker's rhythm (Figure  3-
panel A). The baseline laboratory findings are presented in 
Table 1. Renal function test was severely disturbed (creati-
nine = 5.4 mg/dL), and she had also hyponatremia (serum 
sodium = 126 meq/dL) and mild hyperkalemia (serum po-
tassium  =  5  meq/dL). The baseline liver function test was 
within normal limits.
Emergent limited bedside TTE at emergency department 
(ED) showed massive pericardial effusion (PE) with a maxi-
mal depth of 3 cm and evidence of cardiac tamponade. She was 
urgently transferred to the operating room for the PE drainage.
Postdrainage TTE showed moderate left ventricu-
lar enlargement, LVEF  =  30%, moderate-to-severe MR, 
mild-to-moderate tricuspid regurgitation, a PAP of 45 mm Hg, 
and small PE. The current echocardiography showed a signif-
icant reduction in her LV function considering her previous 
TTE report (2 months earlier), which was completely within 
normal limits.
After surgery, the extubation was impossible due to the re-
spiratory distress and development of hypoxemia during the 
weaning process and she got febrile.
Chest CT showed bilateral confluent consolidations pre-
dominantly in upper and middle zones with more severity in 
right side highly suggestive of COVID-19 (Figure 3-panel B).
She was isolated in ICU, and the nasopharyngeal swab 
specimen was reported positive for COVID-19 in RT-PCR 
test.
2.3.3 | Outcome
The patient's status deteriorated, and she underwent shock 
and unfortunately died after about 50  days. She received 
Kaletra and IVIG to control COVID-19 infection, accompa-
nied with vasopressor support and hemodialysis.
The pericardial fluid analysis was compatible with an ex-
udate nature with a negative cytology. The pericardial biopsy 
was negative for malignancy and tuberculosis.
2.4 | Case 4
2.4.1 | Case history
The patient is a 22-year-old healthy man with compressive 
chest pain, dyspnea, and back pain without a sore throat, 
dyspnea, and cough and had no history of close contact with 
a COVID-19-positive patient. He was a nonsmoker, and his 
past medical and drug history were negative.
F I G U R E  3  A, ECG of case 3 showing 
pacemaker's rhythm. B, Chest CT of case 3 
showing bilateral confluent consolidations 
predominantly in upper and middle zones 
with more severity in right side
(A) (B)
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On presentation, he had SPO2 = 93%, systolic blood pres-
sure of upper extremities was about 60 mm Hg, and the BP 
of lower extremities was 140/60 mm Hg. His heart rate was 
90 bpm, and temperature was 38.1 degree Celsius. The phys-
ical examination was unremarkable except for impalpable 
pulse of left upper limb and weak pulse of right upper limb. 
He did not have any sign of Marfan syndrome.
2.4.2 | Differential diagnosis, 
investigations, and treatment
His ECG was within normal limits (Figure  4-panel A). 
Emergent TTE showed a normal LV size with LVEF of 50%-
55%, normal RV size and function, mild MR, tricuspid aortic 
valve and moderate aortic insufficiency, no aortic stenosis, 
and dilated ascending aorta (5.1 cm); flap of dissection was 
seen in ascending aorta originating from sinotubular junction 
and extending to aortic arch, descending aorta and abdomi-
nal aorta. The left subclavian artery originated from the false 
lumen. No PE was observed. The laboratory data are pre-
sented in table 1.
The patient was emergently transferred to CT department 
where chest CT, aortic CT angiography, and coronary angi-
ography were performed for him.
Coronary CT angiography showed normal coronary 
arteries.
Aortic CT angiography showed type A aortic dissection. 
The intimal flap started at distal part of the ascending aorta 
with extension to abdominal aorta and terminated distal to 
the renal arteries. Dissection flap extension to brachioce-
phalic artery, left common carotid and left subclavian artery 
were noted. Both true and false lumens were patent. Distal 
abdominal aorta and iliac arteries were intact (Figure 4-panel 
B).
Chest CT showed multifocal confluent round-shaped 
consolidations in left lower lobe mostly compatible with 
COVID-19 (Figure 4-panel C).
The laboratory findings are presented in Table  1. The 
renal and liver function tests were normal.
The patient was scheduled for emergent surgery for acute 
aortic dissection, but after being informed of the potential 
COVID-19, he and his family refused the surgery in our cen-
ter and asked for transfer to a COVID-19 dedicated center 
with cardiac surgery facilities. Despite explaining that he 
may be endangered during transfer, he was transferred to 
another center by a fully equipped ambulance after taking 
signed self-informed consent.
2.4.3 | Outcome
The phone follow-up on the following days revealed that he 
had undergone cardiac surgery successfully. We could not 
get access to his further clinical course and medical thera-
pies, but our further phone follow-up revealed that he was 
discharged from hospital after several weeks with good con-
ditions. However, the first RT-PCR of nasopharyngeal swab 
test sent by our center was negative.
3 |  DISCUSSION
Case 1 was initially manifested with cardiac-related symp-
toms and signs and developed a typical form of COVID 
pneumonitis later. This patient had a history of hypertension, 
F I G U R E  4  A, Normal ECG of case 
4. B, Aortic CT angiography of case 4 
showing tear in aorta. C, Chest CT of case 4 
showing multifocal confluent round-shaped 
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which is one of the very important comorbidities and risk 
factors for progression of COVID-19 into its severe forms. 
Although his illness rapidly progressed and the lung involve-
ment was significant, and despite history of HTN, he did not 
progress to acute respiratory distress syndrome or shock and 
responded well to the therapies.
We continued his ACEI (captopril) to control his blood 
pressure and due to its beneficial effects on his LV function 
during his disease course and on discharge.
Regardless of many clinicians' concerns about suscepti-
bility to coronavirus in those patients who are taking ACEIs 
or ARBS, observational studies have not provided convinc-
ing data on whether these drugs have potentially beneficial 
or harmful effects on COVID-19 patients. It has been shown 
that worse outcomes may be more prevalent in hypertensive 
and diabetic patients, possibly due to overexpression of an-
giotensin-converting enzyme 2 (ACE-2) receptors in alveo-
lar epithelial cells. Some researchers speculate that as using 
ACEIs and ARBs upregulate ACE-2 expression, theoretically 
this effect could increase the virus entry and risk for COVID-
19 or disease severity. In contrast, some investigators have 
postulated some mechanisms for the beneficial effects of 
these drugs. To exemplify, upregulating ACE2 with ACEI or 
ARBs could enhance the conversion of angiotensin II to an-
giotensin 1-7 which has anti-inflammatory and vasodilatory 
properties. Nevertheless, professional societies such as ACC/
AHA have recommended that patients receiving these drugs 
should continue taking them.3,8,10-13
Decision-making under uncertainty would be stressful in 
such settings. However, we decided to continue the ACEI be-
cause we postulated that stopping the drug in a compensated 
heart failure patient might be more harmful.3,14,15
Another issue regarding the current patient is the develop-
ment of non-ST elevation MI (NSTEMI) after controlling his 
pneumonitis. As shown earlier, the endothelial dysfunction in 
the setting of coronavirus infection may lead to the plaque in-
stability, microvascular dysfunction, and thrombus formation 
in previously diseased coronary arteries. On the other hand, 
prolonged hypoxemia in this patient could be considered a 
predisposing factor for MI development.
The second case is another example of an acute thrombotic 
event as the first presentation of COVID-19. Although he was 
in his first 3 months after coronary angioplasty, in which the 
risk of acute thrombosis is high, an increased risk for the stent 
thrombosis by COVID-19 could not be simply ruled out.3,14,16,17
There are some reports regarding the early stent throm-
bosis in COVID-19 patients with acute MI patients having 
undergone primary PCI. To the best of our knowledge, this 
case may be the first reported case of in-stent thrombosis in a 
COVID-19 patient with history of chronic PCI.
The mechanism of increased risk of stent thrombosis may 
be the increased platelets' aggregability accompanied with 
other pathophysiological mechanisms mentioned earlier, 
such as endothelial dysfunction.
For the third case, although patients who are under he-
modialysis are predisposed to uremic pericarditis and tam-
ponade, this patient did not reveal any history of missing her 
routine hemodialysis. Hua et al have reported the first case 
of tamponade complicating myopericarditis in a 47-year-old 
lady.18 Considering the clinical and laboratory findings of the 
current patient, it seems that our patient is another case of 
COVID-19 myopericarditis.
The fourth case shows the development of aortic dissec-
tion in an otherwise normal individual probably infected with 
novel coronavirus. Although the RT-PCR for novel coronavi-
rus was negative, the other laboratory findings and the chest 
CT were highly suggestive of COVID-19.
Fukuhara et al have reported an acute type A aortic dis-
section in a healthy nonsmoker man who initially did not 
have any signs of COVID-19, and on the 5th day after a suc-
cessful surgery, he developed bilateral lung infiltrate which 
progressed to ARDS and death and a positive RT-PCR for 
COVID-19.19 They did not consider the COVID-19 the pos-
sible cause of aortic dissection and aimed to highlight the 
importance of being always ready to encounter COVID-19 
in any patient with any complaint and to assume all patients 
may have been exposed to COVID-19. However, the novel 
coronavirus has surprised the clinicians and investigators 
since its first appearance. It can invade everywhere in the 
body, and in these cases, large vessel arteritis could not be 
simply ruled out.
ACKNOWLEDGMENTS
We would like to acknowledge the help provided by Mr. 





NN and MMAR: contributed to acquisition of data, drafting 
the manuscript, final revision of the manuscript, and partici-
pated sufficiently in the work. MB, ZH, MEZ, PR, MK, SM, 
PM, and SA: contributed to acquisition of data, drafting the 
manuscript, and participated sufficiently in the work.
ETHICAL APPROVAL
Informed consent was acquired from patients to report their 
data. The ethical committee of Rajaie Cardiovascular Medical 
and Research Center approved this case series.
ORCID
Nasim Naderi   https://orcid.org/0000-0001-6067-040X 
2442 |   NADERI Et Al.
Mohammad Mostafa Ansari Ramandi   https://orcid.
org/0000-0002-7431-0373 
Shirin Manshouri   https://orcid.
org/0000-0001-5680-8111 
REFERENCES
 1. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 de-
ceased patients with coronavirus disease 2019: retrospective study. 
BMJ. 2019;368:m1091.
 2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mor-
tality of adult inpatients with COVID-19 in Wuhan, China: a retro-
spective cohort study. Lancet. 2020;395:1054-1062.
 3. Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the 
cardiovascular system: implications for risk assessment, diag-
nosis, and treatment options. Cardiovasc Res. 2020. https://doi.
org/10.1093/cvr/cvaa106
 4. Huang C, Wang Y, Li X, et al. Clinical features of patients in-
fected with 2019 novel coronavirus in Wuhan, China. Lancet. 
2020;395(10223):497-506.
 5. Wan S, Xiang Y, Fang W, et al. Clinical features and treatment 
of COVID-19 patients in northeast Chongqing. J Med Virol. 
2020;92(7):797-806.
 6. Wang L, He W, Yu X, et al. Coronavirus Disease 2019 in elderly 
patients: characteristics and prognostic factors based on 4-week 
follow-up. J Infect. 2020;80(6):639-645.
 7. Ansari Ramandi MM, Baay M, Naderi N. Does the novel coro-
navirus 2019 like heart more than the other family members of 
coronaviruses?. Journal of Cardiovascular and Thoracic Research. 
2020;12(2):156–157. http://dx.doi.org/10.34172/ jcvtr.2020.27
 8. Guo J, Huang Z, Lin L, Lv J. Coronavirus disease 2019 (COVID-19) 
and cardiovascular disease: a viewpoint on the potential influence 
of angiotensin-converting enzyme inhibitors/angiotensin receptor 
blockers on onset and severity of severe acute respiratory syndrome 
coronavirus 2 infection. J Am Heart Assoc. 2020;9(7):e016219.
 9. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal 
outcomes of patients with coronavirus disease 2019 (COVID-19). 
JAMA Cardiol. 2020;5(7):811.
 10. Rico-Mesa JS, White A, Anderson AS. Outcomes in patients 
with COVID-19 infection taking ACEI/ARB. Curr Cardiol Rep. 
2020;22(5):31.
 11. Patel AB, Verma A. COVID-19 and angiotensin-converting en-
zyme inhibitors and angiotensin receptor blockers: what is the evi-
dence? JAMA. 2020;323:1769–1770.
 12. Sommerstein R, Kochen MM, Messerli FH, Gräni C. Coronavirus 
disease 2019 (COVID-19): do angiotensin-converting enzyme in-
hibitors/angiotensin receptor blockers have a biphasic effect? J Am 
Heart Assoc. 2020;9(7):e016509.
 13. Bozkurt B, Kovacs R, Harrington B. HFSA/ACC/AHA statement 
addresses concerns re: using RAAS antagonists in COVID-19. Am 
Heart Assoc Professional Heart Daily. 2020;26:370. 
 14. Dominguez-Erquicia P, Dobarro D, Raposeiras-Roubín S, Bastos-
Fernandez G, Iñiguez-Romo A. Multivessel coronary thrombosis in 
a patient with COVID-19 pneumonia. Eur Heart J. 2020;41:2132.
 15. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune 
pathogenesis and diagnosis of COVID-19. J Pharm Anal. 
2020;10(2):102-108.
 16. Lacour T, Semaan C, Genet T, Ivanes F. Insights for increased 
risk of failed fibrinolytic therapy and stent thrombosis associated 
with COVID-19 in ST-segment elevation myocardial infarction pa-
tients. Catheter Cardiovasc Interv. 2020. https://doi.org/10.1002/
ccd.28948
 17. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated in-
flammatory responses: from mechanisms to potential therapeutic 
tools. Virologica Sinica. 2020;35:266-271.
 18. Hua A, O'Gallagher K, Sado D, Byrne J. Life-threatening car-
diac tamponade complicating myo-pericarditis in COVID-19. Eur 
Heart J. 2020;41(22):2130.
 19. Fukuhara S, Rosati CM, El-Dalati S. Acute type A aortic dissec-
tion during COVID-19 outbreak. Ann Thorac Surg.https://doi.
org/10.1016/j.athor acsur.2020.04.008
How to cite this article: Naderi N, Ansari Ramandi 
MM, Baay M, et al. Cardiovascular patients in 
COVID-19 era, a case series, an experience from a 
tertiary cardiovascular center in Tehran, Iran. Clin Case 
Rep. 2020;8:2436–2442. https://doi.org/10.1002/
ccr3.3163
